Table 2.

Adjusted means of sex hormones by quartiles of percent density stratified by history of hormone therapy use

Never used hormone therapy (n = 45)
Former users of hormone therapy (n = 43)
Used hormone therapy <5 y ago (n = 20)
Used hormone therapy ≥5 y ago (n = 19)
Adjusted hormone levels by quartiles of percent density* (95% CI)Adjusted hormone levels by quartiles of percent density* (95% CI)Adjusted hormone levels by quartiles of percent density (95% CI)Adjusted hormone levels by quartiles of percent density (95% CI)
Estrone (pg/mL)43.7 (35.9-53.2)52.6 (44.2-62.5)66.4 (46.1-95.8)47.9 (36.2-63.3)
51.2 (43.5-60.3)50.6 (41.0-62.6)46.6 (31.2-69.7)59.1 (38.1-91.4)
44.7 (37.3-53.6)39.8 (32.6-48.6)38.3 (26.7-55.0)39.6 (25.7-61.1)
46.0 (38.1-55.6)34.6 (28.8-41.7)33.5 (23.8-47.1)39.5 (25.7-60.8)
    P for trend0.960.010.010.17
Estradiol (pg/mL)16.8 (13.9-20.2)20.2 (17.1-23.8)23.6 (16.9-33.3)19.6 (15.2-25.3)
18.9 (16.2-22.1)18.7 (15.3-22.9)15.2 (10.5-22.0)24.1 (16.1-35.9)
17.9 (15.1-21.3)15.8 (13.1-19.1)15.5 (11.1-21.6)14.9 (10.0-22.1)
19.6 (16.4-23.5)14.0 (11.8-16.7)12.9 (9.4-17.5)18.1 (12.1-26.7)
    P for trend0.350.0030.0250.24
Free estradiol (pg/mL)0.40 (0.32-0.50)0.53 (0.44-0.65)0.68 (0.47-0.98)0.50 (0.38-0.67)
0.53 (0.45-0.64)0.51 (0.40-0.64)0.40 (0.27-0.60)0.66 (0.43-1.0)
0.47 (0.39-0.58)0.45 (0.36-0.56)0.43 (0.30-0.62)0.46 (0.30-0.71)
0.52 (0.43-0.65)0.36 (0.30-0.45)0.34 (0.24-0.48)0.51 (0.33-0.78)
    P for trend0.210.0040.0230.10
Testosterone (pg/mL)188 (145-243)264 (210-331)327 (204-523)249 (174-357)
260 (209-323)223 (169-296)186 (110-312)253 (143-444)
225 (177-286)188 (144-244)215 (135-342)179 (102-312)
206 (161-265)164 (129-210)166 (107-258)168 (97-293)
    P for trend0.930.040.070.77
Free testosterone (pg/mL)3.5 (2.7-4.6)5.6 (4.4-7.0)7.8 (5.1-12.0)5.0 (3.6-6.9)
6.0 (4.9-7.5)4.9 (3.7-6.4)3.8 (2.4-6.2)5.6 (3.3-9.4)
4.8 (3.8-6.1)4.4 (3.4-5.8)4.9 (3.2-7.5)4.7 (2.8-7.8)
4.4 (3.4-5.7)3.3 (2.6-4.3)3.5 (2.3-5.2)3.9 (2.3-6.4)
    P for trend0.550.020.030.28
Androstenedione (ng/mL)444 (351-560)708 (576-871)851 (550-1,315)674 (484-941)
633 (521-770)674 (523-868)557 (344-900)764 (454-1,288)
561 (452-696)466 (368-592)507 (329-780)465 (278-778)
636 (507-797)397 (318-494)366 (244-550)421 (252-704)
    P for trend0.09<0.0010.010.46
DHEA (ng/mL)1.8 (1.3-2.6)3.0 (2.2-4.1)4.4 (2.4-8.0)2.6 (1.6-4.1)
2.7 (2.0-3.6)2.9 (2.0-4.3)2.0 (1.0-3.9)4.5 (2.2-9.2)
2.2 (1.6-3.1)2.1 (1.4-3.0)1.6 (0.9-2.9)2.6 (1.3-5.4)
2.5 (1.8-3.6)1.6 (1.1-2.2)1.3 (0.7-2.3)1.6 (0.8-3.2)
    P for trend0.350.010.010.19
DHEA sulfate (μg/mL)45.4 (29.6-69.7)76.4 (51.1-114.2)101.9 (49.6-209.4)64.3 (35.2-117.4)
55.8 (37.7-82.7)65.0 (40.9-103.3)42.1 (18.9-93.6)104.4 (43.1-252.7)
53.9 (35.3-82.2)82.7 (53.5-127.9)68.5 (33.1-141.6)104.4 (44.4-245.4)
51.6 (34.0-78.2)38.4 (25.3-58.5)26.5 (13.4-52.2)35.0 (12.5-97.5)
    P for trend0.770.100.040.24
SHBG (nmol/L)46.1 (34.3-61.8)36.5 (28.2-47.4)28.8 (18.8-44.0)40.6 (23.3-56.1)
30.0 (23.5-38.4)35.7 (26.0-49.0)39.1 (24.5-62.4)35.0 (21.1-58.2)
36.4 (27.8-47.8)28.3 (21.0-38.2)31.7 (20.8-8.2)23.4 (14.2-38.7)
35.4 (26.6-47.1)38.7 (29.4-51.1)37.5 (25.2-55.7)31.2 (18.9-51.5)
    P for trend0.480.630.480.12
Follicle-stimulating hormone (mIU/L)63.1 (51.2-77.8)52.7 (43.8-63.4)46.2 (34.3-62.3)55.9 (44.5-70.2)
68.5 (57.5-81.6)58.3 (46.4-73.1)60.3 (43.4-83.8)54.9 (38.4-78.4)
72.5 (59.8-88.0)72.8 (58.8-90.1)85.8 (63.1-114.0)66.6 (46.8-94.9)
55.8 (45.5-68.3)63.3 (52.0-77.1)75.8 (57.4-100.0)51.4 (36.1-73.1)
    P for trend0.480.060.010.05
  • * Quartiles of percent density: first quartile: 0.2% to 2.75% (n = 9 never users and 13 former users); second quartile: 2.8% to 4.9% (n = 14 never users and 8 former users); third quartile: 5.1% to 7.5% (n = 11 never users and 11 former users); and fourth quartile: 7.5% to 26.1% (n = 11 never users and 11 former users). Adjusted for age, ethnicity, years since menopause, and percent body fat.

  • Quartiles of percent density: first quartile: 0.2% to 2.75% (n = 4 users <5 years and 8 users ≥5 years); second quartile: 2.8% to 4.9% (n = 4 users <5 years and 4 users ≥5 years); third quartile: 5.1% to 7.5% (n = 6 users <5 years and 4 users ≥5 years); and fourth quartile: 7.5% to 26.1% (n = 6 users <5 years and 3 users ≥5 years). Adjusted for age, ethnicity, years since menopause, and percent body fat.

  • P < 0.05, compared with first quartile.